LEXICON PHARMACEUTICALS, INC. Repayments of Long-Term Debt
LEXICON PHARMACEUTICALS, INC. (LXRX) reported Repayments of Long-Term Debt of -$48.87 million for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-03.
Discontinued › Cash Flow › Financing Activities
us-gaap:RepaymentsOfLongTermDebt · last filed 2023-03-03
- LEXICON PHARMACEUTICALS, INC. repayments of long-term debt for the quarter ending 2021-12-31 was $11.70M, a 101.03% increase year-over-year.
- LEXICON PHARMACEUTICALS, INC. repayments of long-term debt for the quarter ending 2021-09-30 was $0.00, a 100.00% decline year-over-year.
- LEXICON PHARMACEUTICALS, INC. repayments of long-term debt for the quarter ending 2021-06-30 was $0.00, a 100.00% decline year-over-year.
- LEXICON PHARMACEUTICALS, INC. repayments of long-term debt for the quarter ending 2021-03-31 was $0.00, a 100.00% decline year-over-year.
- LEXICON PHARMACEUTICALS, INC. repayments of long-term debt for fiscal 2022 was -$48.87M, a 517.68% decline from fiscal 2021.
- LEXICON PHARMACEUTICALS, INC. repayments of long-term debt for fiscal 2021 was $11.70M, a 94.60% decline from fiscal 2020.
- LEXICON PHARMACEUTICALS, INC. repayments of long-term debt for fiscal 2020 was $216.58M, a 16754.47% increase from fiscal 2019.
- LEXICON PHARMACEUTICALS, INC. repayments of long-term debt for fiscal 2019 was $1.28M, a 91.16% decline from fiscal 2018.
| Period end | Repayments of Long-term Debt 3 month | Repayments of Long-term Debt 6 month | Repayments of Long-term Debt 9 month | Repayments of Long-term Debt 12 month |
|---|---|---|---|---|
| 2022-12-31 | -$48.87M 10-K · filed 2023-03-03 | |||
| 2021-12-31 | $11.70M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-03 | $11.70M derived: sum of 2 quarters · filed 2023-03-03 | $11.70M derived: sum of 3 quarters · filed 2023-03-03 | $11.70M 10-K · filed 2023-03-03 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $0.00 derived: sum of 2 quarters · filed 2021-11-09 | $0.00 10-Q · filed 2021-11-09 | $5.82M derived: sum of 4 quarters · filed 2023-03-03 |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-06 | $0.00 10-Q · filed 2021-08-06 | $5.82M derived: sum of 3 quarters · filed 2023-03-03 | $215.94M derived: sum of 4 quarters · filed 2023-03-03 |
| 2021-03-31 | $0.00 10-Q · filed 2021-05-06 | $5.82M derived: sum of 2 quarters · filed 2023-03-03 | $215.94M derived: sum of 3 quarters · filed 2023-03-03 | $216.26M derived: sum of 4 quarters · filed 2023-03-03 |
| 2020-12-31 | $5.82M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-03 | $215.94M derived: sum of 2 quarters · filed 2023-03-03 | $216.26M derived: sum of 3 quarters · filed 2023-03-03 | $216.58M 10-K · filed 2023-03-03 |
| 2020-09-30 | $210.12M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $210.44M derived: sum of 2 quarters · filed 2021-11-09 | $210.76M 10-Q · filed 2021-11-09 | $211.08M derived: sum of 4 quarters · filed 2022-03-10 |
| 2020-06-30 | $322.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-06 | $643.00K 10-Q · filed 2021-08-06 | $965.00K derived: sum of 3 quarters · filed 2022-03-10 | $1.28M derived: sum of 4 quarters · filed 2022-03-10 |
| 2020-03-31 | $321.00K 10-Q · filed 2021-05-06 | $643.00K derived: sum of 2 quarters · filed 2022-03-10 | $963.00K derived: sum of 3 quarters · filed 2022-03-10 | $1.28M derived: sum of 4 quarters · filed 2022-03-10 |
| 2019-12-31 | $322.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | $642.00K derived: sum of 2 quarters · filed 2022-03-10 | $964.00K derived: sum of 3 quarters · filed 2022-03-10 | $1.28M 10-K · filed 2022-03-10 |
| 2019-09-30 | $320.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-30 | $642.00K derived: sum of 2 quarters · filed 2020-10-30 | $963.00K 10-Q · filed 2020-10-30 | $1.28M derived: sum of 4 quarters · filed 2021-03-12 |
| 2019-06-30 | $322.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-29 | $643.00K 10-Q · filed 2020-07-29 | $964.00K derived: sum of 3 quarters · filed 2021-03-12 | $14.01M derived: sum of 4 quarters · filed 2021-03-12 |
| 2019-03-31 | $321.00K 10-Q · filed 2020-04-27 | $642.00K derived: sum of 2 quarters · filed 2021-03-12 | $13.69M derived: sum of 3 quarters · filed 2021-03-12 | $14.27M derived: sum of 4 quarters · filed 2021-03-12 |
| 2018-12-31 | $321.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-12 | $13.36M derived: sum of 2 quarters · filed 2021-03-12 | $13.95M derived: sum of 3 quarters · filed 2021-03-12 | $14.53M 10-K · filed 2021-03-12 |
| 2018-09-30 | $13.04M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | $13.63M derived: sum of 2 quarters · filed 2019-11-07 | $14.21M 10-Q · filed 2019-11-07 | $14.78M derived: sum of 4 quarters · filed 2020-03-12 |
| 2018-06-30 | $588.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-01 | $1.17M 10-Q · filed 2019-08-01 | $1.74M derived: sum of 3 quarters · filed 2020-03-12 | $2.29M derived: sum of 4 quarters · filed 2020-03-12 |
| 2018-03-31 | $581.00K 10-Q · filed 2019-05-01 | $1.15M derived: sum of 2 quarters · filed 2020-03-12 | $1.70M derived: sum of 3 quarters · filed 2020-03-12 | $2.33M derived: sum of 4 quarters · filed 2020-03-12 |
| 2017-12-31 | $566.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | $1.12M derived: sum of 2 quarters · filed 2020-03-12 | $1.74M derived: sum of 3 quarters · filed 2020-03-12 | $2.28M 10-K · filed 2020-03-12 |
| 2017-09-30 | $552.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-01 | $1.18M derived: sum of 2 quarters · filed 2018-11-01 | $1.71M 10-Q · filed 2018-11-01 | $2.23M derived: sum of 4 quarters · filed 2019-03-15 |
| 2017-06-30 | $626.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-07-30 | $1.16M 10-Q · filed 2018-07-30 | $1.68M derived: sum of 3 quarters · filed 2019-03-15 | $2.19M derived: sum of 4 quarters · filed 2019-03-15 |
| 2017-03-31 | $536.00K 10-Q · filed 2018-05-03 | $1.06M derived: sum of 2 quarters · filed 2019-03-15 | $1.56M derived: sum of 3 quarters · filed 2019-03-15 | $2.06M derived: sum of 4 quarters · filed 2019-03-15 |
| 2016-12-31 | $521.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-15 | $1.03M derived: sum of 2 quarters · filed 2019-03-15 | $1.52M derived: sum of 3 quarters · filed 2019-03-15 | $2.02M 10-K · filed 2019-03-15 |
| 2016-09-30 | $507.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | $1.00M derived: sum of 2 quarters · filed 2017-11-08 | $1.50M 10-Q · filed 2017-11-08 | $1.98M derived: sum of 4 quarters · filed 2018-03-01 |
| 2016-06-30 | $497.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-01 | $988.00K 10-Q · filed 2017-08-01 | $1.47M derived: sum of 3 quarters · filed 2018-03-01 | $1.94M derived: sum of 4 quarters · filed 2018-03-01 |
| 2016-03-31 | $491.00K 10-Q · filed 2017-05-04 | $971.00K derived: sum of 2 quarters · filed 2018-03-01 | $1.44M derived: sum of 3 quarters · filed 2018-03-01 | $1.89M derived: sum of 4 quarters · filed 2018-03-01 |
| 2015-12-31 | $480.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-01 | $947.00K derived: sum of 2 quarters · filed 2018-03-01 | $1.40M derived: sum of 3 quarters · filed 2018-03-01 | $1.86M 10-K · filed 2018-03-01 |
| 2015-09-30 | $467.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-07 | $923.00K derived: sum of 2 quarters · filed 2016-11-07 | $1.38M 10-Q · filed 2016-11-07 | $1.82M derived: sum of 4 quarters · filed 2017-03-06 |
| 2015-06-30 | $456.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04 | $912.00K 10-Q · filed 2016-08-04 | $1.35M derived: sum of 3 quarters · filed 2017-03-06 | $1.78M derived: sum of 4 quarters · filed 2017-03-06 |
| 2015-03-31 | $456.00K 10-Q · filed 2016-05-05 | $898.00K derived: sum of 2 quarters · filed 2017-03-06 | $1.33M derived: sum of 3 quarters · filed 2017-03-06 | $1.75M derived: sum of 4 quarters · filed 2017-03-06 |
| 2014-12-31 | $442.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-06 | $871.00K derived: sum of 2 quarters · filed 2017-03-06 | $1.29M derived: sum of 3 quarters · filed 2017-03-06 | $1.71M 10-K · filed 2017-03-06 |
| 2014-09-30 | $429.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-09 | $848.00K derived: sum of 2 quarters · filed 2015-11-09 | $1.27M 10-Q · filed 2015-11-09 | $1.68M derived: sum of 4 quarters · filed 2016-03-11 |
| 2014-06-30 | $419.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-07 | $839.00K 10-Q · filed 2015-08-07 | $1.25M derived: sum of 3 quarters · filed 2016-03-11 | $1.64M derived: sum of 4 quarters · filed 2016-03-11 |
| 2014-03-31 | $420.00K 10-Q · filed 2015-05-05 | $827.00K derived: sum of 2 quarters · filed 2016-03-11 | $1.22M derived: sum of 3 quarters · filed 2016-03-11 | $1.61M derived: sum of 4 quarters · filed 2016-03-11 |
| 2013-12-31 | $407.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-11 | $801.00K derived: sum of 2 quarters · filed 2016-03-11 | $1.19M derived: sum of 3 quarters · filed 2016-03-11 | $1.57M 10-K · filed 2016-03-11 |
| 2013-09-30 | $394.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-06 | $780.00K derived: sum of 2 quarters · filed 2014-11-06 | $1.17M 10-Q · filed 2014-11-06 | $1.54M derived: sum of 4 quarters · filed 2015-03-12 |
| 2013-06-30 | $386.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-07 | $773.00K 10-Q · filed 2014-08-07 | $1.15M derived: sum of 3 quarters · filed 2015-03-12 | $1.51M derived: sum of 4 quarters · filed 2015-03-12 |
| 2013-03-31 | $387.00K 10-Q · filed 2014-05-08 | $762.00K derived: sum of 2 quarters · filed 2015-03-12 | $1.12M derived: sum of 3 quarters · filed 2015-03-12 | $1.48M derived: sum of 4 quarters · filed 2015-03-12 |
| 2012-12-31 | $375.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-12 | $737.00K derived: sum of 2 quarters · filed 2015-03-12 | $1.09M derived: sum of 3 quarters · filed 2015-03-12 | $1.44M 10-K · filed 2015-03-12 |
| 2012-09-30 | $362.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-12 | $715.00K derived: sum of 2 quarters · filed 2013-11-12 | $1.07M 10-Q · filed 2013-11-12 | $1.41M derived: sum of 4 quarters · filed 2014-03-07 |
| 2012-06-30 | $353.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-01 | $706.00K 10-Q · filed 2013-08-01 | $1.05M derived: sum of 3 quarters · filed 2014-03-07 | $1.38M derived: sum of 4 quarters · filed 2014-03-07 |
| 2012-03-31 | $353.00K 10-Q · filed 2013-05-10 | $698.00K derived: sum of 2 quarters · filed 2014-03-07 | $1.03M derived: sum of 3 quarters · filed 2014-03-07 | $3.66M derived: sum of 4 quarters · filed 2014-03-07 |
| 2011-12-31 | $345.00K derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-07 | $674.00K derived: sum of 2 quarters · filed 2014-03-07 | $3.31M derived: sum of 3 quarters · filed 2014-03-07 | $3.59M 10-K · filed 2014-03-07 |
| 2011-09-30 | $329.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-07 | $2.96M derived: sum of 2 quarters · filed 2012-11-07 | $3.24M 10-Q · filed 2012-11-07 | $3.52M derived: sum of 4 quarters · filed 2013-03-11 |
| 2011-06-30 | $2.63M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-02 | $2.92M 10-Q · filed 2012-08-02 | $3.19M derived: sum of 3 quarters · filed 2013-03-11 | $19.45M derived: sum of 4 quarters · filed 2013-03-11 |
| 2011-03-31 | $284.00K 10-Q · filed 2012-05-03 | $555.00K derived: sum of 2 quarters · filed 2013-03-11 | $16.82M derived: sum of 3 quarters · filed 2013-03-11 | |
| 2010-12-31 | $271.00K derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-11 | $16.54M derived: sum of 2 quarters · filed 2013-03-11 | $49.86M 10-K · filed 2013-03-11 | |
| 2010-09-30 | $16.27M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-01 | $49.59M 10-Q · filed 2011-11-01 | ||
| 2010-06-30 | $33.32M 10-Q · filed 2011-08-09 | |||
| 2009-12-31 | $2.12M 10-K · filed 2012-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |